Evidence map›Paper›PMID 32440569›Full record

ArticleMDM policy & practice

Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis.

David W Dowdy, Alice A Zwerling, Andrea Stennett, Alexandra Searle, Vadim Dukhanin, Holly A Taylor, Maria W Merritt

Abstract read
In one paragraph

Article in MDM policy & practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Social stigma in the time of coronavirus disease 2019.The European respiratory journal · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David W DowdyDepartments of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Alice A ZwerlingSchool of Epidemiology & Public Health, University of Ottawa, Ottawa, Canada.
Andrea StennettMental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Alexandra SearleInternational Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Vadim DukhaninHealth Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Holly A TaylorInternational Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Maria W MerrittInternational Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.ORCID https://orcid.org/0000-0003-0651-2405

Funding

Assessing Social Justice in Economic Evaluation to Scale up Novel MDR-TB RegimensR01AI114458 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DOWDY, DAVID WESLEY · 2015 to 2018
$1.6M
NIAID NIH HHS R01 AI114458
6 · The paper itself

Abstract

In making policy decisions with constrained resources, an important consideration is the impact of alternative policy options on social justice. Social justice considers interactions between individuals and society and can be conceptualized across domains of agency, association, and respect. Despite its importance, social justice is rarely considered formally in health policy decision making, partially reflecting challenges in its measurement. We define three criteria for considering social justice in health-related policy decisions: 1) linkage of social justice to a measurable construct; 2) ability to reproducibly and feasibly estimate the impacts of a policy decision on the selected construct; and 3) appropriate presentation to decision makers of the expected social justice implications using that construct. We use preliminary data from qualitative interviews from three groups of respondents in South Africa and Uganda to demonstrate that stigma meets the first of these criteria. We then use the example of policy addressing novel treatment regimens for multidrug-resistant tuberculosis and a validated tuberculosis stigma scale to illustrate how policy effects on stigma could be estimated (criterion 2) and presented to decision makers in the form of justice-enhanced cost-effectiveness analysis (criterion 3). Finally, we provide a point-by-point guide for conducting similar assessments to facilitate consideration of social justice in health-related policy decisions. Our case study and guide for how to make social justice impacts more apparent to decision makers also illustrates the importance of local data and local capacity. Performing social justice assessments alongside more traditional evaluations of cost-effectiveness, budget impact, and burden of disease could help represent data-informed considerations of social justice in health care decision making more broadly.

Indexed as

drug resistancehealth policysocial justicesocial stigmatuberculosis

Identifiers

PMID32440569
PMCPMC7227142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.